Acceleron Pharma (NASDAQ:XLRN) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
A number of other analysts have also issued reports on the company. Credit Suisse Group set a $51.00 target price on Acceleron Pharma and gave the company a “buy” rating in a research report on Tuesday, November 14th. Cann reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, January 8th. HC Wainwright reissued a “buy” rating and issued a $62.00 target price on shares of Acceleron Pharma in a research report on Monday, December 11th. Royal Bank of Canada reissued a “hold” rating on shares of Acceleron Pharma in a research report on Thursday, November 2nd. Finally, Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, December 11th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $44.81.
Shares of Acceleron Pharma (XLRN) opened at $41.71 on Friday. The stock has a market capitalization of $1,955.06, a P/E ratio of -16.10 and a beta of 1.59. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $46.93.
In other Acceleron Pharma news, Director Jean George sold 105,122 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the transaction, the director now owns 1,250 shares in the company, valued at $44,662.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Christopher Rovaldi sold 11,000 shares of the business’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $45.00, for a total transaction of $495,000.00. Following the completion of the transaction, the senior vice president now owns 35,701 shares of the company’s stock, valued at approximately $1,606,545. The disclosure for this sale can be found here. In the last 90 days, insiders sold 146,021 shares of company stock valued at $5,529,598. Insiders own 3.90% of the company’s stock.
Large investors have recently bought and sold shares of the business. Quantbot Technologies LP grew its stake in shares of Acceleron Pharma by 416.3% during the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Acceleron Pharma during the third quarter worth $225,000. Trexquant Investment LP acquired a new position in shares of Acceleron Pharma during the third quarter worth $266,000. PNC Financial Services Group Inc. grew its stake in shares of Acceleron Pharma by 57.8% during the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 3,100 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Acceleron Pharma by 3.9% during the second quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 355 shares in the last quarter. Institutional investors and hedge funds own 85.62% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/02/acceleron-pharma-xlrn-cut-to-hold-at-bidaskclub.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.